CD103(+) T Cells May Be a Useful Biomarker in Borrmann Type 4 Gastric Cancer

Background/Aim: Recently, several studies have reported that CD103+ T cells are associated with antitumor immunity in gastric cancer (GC). However, the significance of CD103+ T cells in Borrmann type 4 GC remains unclear. The aim of this study is to assess the association of CD103+ T cells with type 4 GC. Materials and Methods: Tissue samples obtained from surgically resected specimens of patients with type 4 GC were collected, and immunohistochemical staining was performed to detect the presence of CD103+ T cells. Results: A total of 46 patients were analyzed. In some patients, high CD103 expression was observed, and patients with high CD103 expression tended to have a better prognosis than those with low CD103 expression. In particular, for patients who receive doublet chemotherapy after surgery, high CD103 expression was associated with a good prognosis. Conclusion: CD103+ T cells may be a prognostic marker in type 4 GC.